Journal
CANCER CELL
Volume 17, Issue 4, Pages 388-399Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2010.02.027
Keywords
-
Categories
Funding
- American Society
- Prostate Cancer Foundation
- Stanford University Center for Children's Brain Tumors
- National Institutes of Health
Ask authors/readers for more resources
In a screen of drugs previously tested in humans we identified itraconazole, a systemic antifungal, as a potent antagonist of the Hedgehog (Hh) signaling pathway that acts by a mechanism distinct from its inhibitory effect on fungal sterol biosynthesis. Systemically administered itraconazole, like other Hh pathway antagonists, can suppress Hh pathway activity and the growth of medulloblastoma in a mouse allograft model and does so at serum levels comparable to those in patients undergoing antifungal therapy. Mechanistically, itraconazole appears to act on the essential Hh pathway component Smoothened (SMO) by a mechanism distinct from that of cyclopamine and other known SMO antagonists, and prevents the ciliary accumulation of SMO normally caused by Hh stimulation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available